Literature DB >> 20390387

Thalidomide is a highly effective treatment of MDS: a single-hospital experience in Japan.

Kunio Hayashi, Keiko Hattori, Fumiharu Toi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20390387     DOI： 10.1007/s12185-010-0566-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Response rate and survival after thalidomide-based therapy in 248 patients with myelodysplastic syndromes.

Authors:  A Candoni; A Raza; F Silvestri; L Lisak; N Galili; M Mumtaz; F Kikic; R Fanin
Journal:  Ann Hematol       Date:  2005-03-31       Impact factor: 3.673

Review 2.  The myelodysplastic syndromes: diagnosis and treatment.

Authors:  David P Steensma; John M Bennett
Journal:  Mayo Clin Proc       Date:  2006-01       Impact factor: 7.616

3.  The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes.

Authors:  F Zorat; V Shetty; D Dutt; L Lisak; F Nascimben; K Allampallam; S Dar; A York; S Gezer; P Venugopal; A Raza
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

4.  Thalidomide for the treatment of patients with myelodysplastic syndromes.

Authors:  C Strupp; U Germing; M Aivado; E Misgeld; R Haas; N Gattermann
Journal:  Leukemia       Date:  2002-01       Impact factor: 11.528

5.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

6.  Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

Authors:  A Raza; P Meyer; D Dutt; F Zorat; L Lisak; F Nascimben; M du Randt; C Kaspar; C Goldberg; J Loew; S Dar; S Gezer; P Venugopal; J Zeldis
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

7.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 8.  New approaches to the treatment of myelodysplasia.

Authors:  Alan F List
Journal:  Oncologist       Date:  2002
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.